Mylan CEO Defends EpiPen Price Hike

WASHINGTON (AP) — The head of pharmaceutical company Mylan is defending the cost for life-saving EpiPens.

She’s signaling that the company has no plans to lower prices despite a public outcry and questions from skeptical lawmakers.

In testimony for Congress, CEO Heather Bresch says she believes Mylan has struck a balance between price and access to the drug.

The price of EpiPens has grown to $608 for a two-pack, an increase of more than 500 percent since 2007.

Bresch says the company does not want to go back to a time when awareness of allergic reactions was much lower and many schools did not stock the drug.